NCT04006405 (AUR87A) is a clinical trial of GAG score in Clear Cell Renal Cell Carcinoma, sponsored by Elypta.

Who is sponsoring NCT04006405?

NCT04006405 is sponsored by Elypta.

What drugs are being tested in NCT04006405?

Interventions in NCT04006405: GAG score.

What condition does NCT04006405 study?

NCT04006405 studies Clear Cell Renal Cell Carcinoma.

Is NCT04006405 still recruiting?

NCT04006405 is currently completed. Last updated 15 June 2025.

Last reviewed 2025-06-15 · How we verify

NCT04006405: AUR87A

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Completed Last updated 15 June 2025

What this trial tests

trial testing GAG score in Clear Cell Renal Cell Carcinoma in 280 participants. Completed in 7 May 2025.

Timeline

10 January 2020

Primary endpoint
7 May 2025

7 May 2025

Quick facts

Lead sponsor	Elypta
Status	Completed
Study type	OBSERVATIONAL
Enrollment	280
Start date	10 January 2020
Primary completion	7 May 2025
Estimated completion	7 May 2025
Sites	29 locations across Denmark, France, Finland, Italy, Belgium, Sweden, United Kingdom, Canada

Drugs / interventions tested

GAG score

Conditions studied

Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →

Sponsor

Elypta

Who can join

18 and older, any sex, with Clear Cell Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AUR87A is an observational prospective multicenter diagnostics test cohort study for detection of renal cell carcinoma recurrence as determined by the reference standard, which is imaging using computed tomography (CT) of the chest and abdomen at defined intervals after primary surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.
Li M, Li L, Zheng J, Li Z, et al · · 2023 · cited 57× · PMID 36810071 · DOI 10.1186/s12943-023-01745-7
Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma-A Prospective Cohort Study.
Gatto F, Dabestani S, Bratulic S, Limeta A, et al · · 2022 · cited 12× · PMID 35911082 · DOI 10.1016/j.euros.2022.06.003
Modeling for understanding and engineering metabolism.
Nielsen J, Petranovic D. · · 2025 · cited 2× · PMID 40070847 · DOI 10.1017/qrd.2025.1

Verify or expand the search:

Other trials of GAG score

Trials testing the same drug.

NCT05028660 — AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study · completed

Other recruiting trials for Clear Cell Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting

Other Elypta trials

Trials by the same sponsor.

NCT05028660 — AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04006405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elypta
Last refreshed: 15 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04006405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing